Overview

Early Versus Late Post Caesarean Section Oral Anticoagulation Initiation and Risk of Maternal Complications in Patients With Mechanical Heart Valve Prosthesis

Status:
Recruiting

Trial end date:
2022-03-01

Target enrollment:
0

Participant gender:
Female

Summary

A randomized cohort study applied to patients with mechanical heart valve prosthesis who will be delivered by caesarean section at or after 28 weeks of gestation . Using a table of random numbers, participants will be divided into 2 equal groups. Group A (57 patients) in which warfarin will be started day 2 after caesarean delivery (i.e. 24 hours postoperative), and group B (57 patients) in which warfarin will be started day 5 after caesarean delivery, then maternal complications are compared among these 2 groups.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Cairo University

Treatments:

Warfarin

Criteria

Inclusion Criteria:

- Pregnant women with mechanical prosthetic heart valves who are planned to deliver by
caesarean delivery, provided that the gestational age at delivery is 28 weeks of
gestation or more whether singleton or multi-fetal pregnancy.

Exclusion Criteria:

- Patients with right-sided mechanical heart valves.

- Patients with a history of any thrombotic events e.g. Stuck prosthetic valve, or
cerebrovascular stroke, etc.

- Patients with hypertensive disorders.

- Diabetic patients.

- Patients with known bleeding disorders or coagulation defects.

- Patients with known thrombophilia.

- Patients who refuse to share in the study.